Trials / Completed
CompletedNCT00124098
An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD)
An Open-Label Study of Aranesp® (Darbepoetin Alfa) Administration Once Every Four Weeks in Anaemic Chronic Kidney Disease (CKD) Subjects
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess if Aranesp® administered once every 4 weeks to chronic kidney disease subjects is safe and efficacious in maintaining haemoglobin levels greater than or equal to 100 g/L.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aranesp® (darbepoetin alfa) |
Timeline
- First posted
- 2005-07-27
- Last updated
- 2008-06-16
Source: ClinicalTrials.gov record NCT00124098. Inclusion in this directory is not an endorsement.